Prof. Bellmunt has acted as principle investigator on numerous clinical trials in his specialized field; his research efforts have primarily focused on the use of immunotherapy in the treatment of genitourinary malignancies, with a growing interest in the value of implementing prospective patient data into clinical trials to improve our understanding of the underlying genetic and biological mechanisms of response and resistance.
He is a founding member and past-president of Grupo Español de Tumores Genitourinarios, and has served on the Scientific Committee at the American Society of Clinical Oncology-Genitourinary Symposium.
He has published extensively in his field (with more than 450 peer-reviewed publications and more than 100 book or congress contributions to his name), and, as an active member of numerous national and international oncology associations, has been instrumental in developing treatment guidelines for the European Association of Urology, the European Society of Medical Oncology, Sociedad Española de Oncología Médica, and the US Society for Immunotherapy of Cancer.